LCM
HUMA icon

Lazari Capital Management’s Humacyte HUMA Stock Holding History

Lazari Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3K Buy
14,444
+1,300
+10% +$1.21K ﹤0.01% 188
2026
Q1 		$7.97K Hold
13,144
– – ﹤0.01% 175
2025
Q4 		$12.6K Buy
13,144
+100
+0.8% +$142 ﹤0.01% 164
2025
Q3 		$22.7K Hold
13,044
– – 0.01% 163
2025
Q2 		$27.3K Buy
+13,044
New +$25.1K 0.01% 153

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lazari Capital Management's HUMA Position: Q2 2026 in Review

Lazari Capital Management increased its Humacyte (HUMA) stake by 9.9% in Q2 2026, buying an estimated $1.21K and bringing the position to 14,444 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #188.

Lazari Capital Management first reported a position in HUMA in Q2 2025 and has held it in 5 quarters since. The position peaked at $27.3K in Q2 2025. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Lazari Capital Management held 14,444 shares of Humacyte worth $11.3K as of Q2 2026.
  • Lazari Capital Management bought 1,300 Humacyte shares in Q2 2026, an estimated $1.21K.
  • Humacyte made up ﹤0.01% of Lazari Capital Management's portfolio in Q2 2026, its #188 holding.
  • Lazari Capital Management first reported a position in Humacyte in Q2 2025 and has held it in 5 quarters since.
  • Lazari Capital Management's Humacyte position peaked at $27.3K in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Lazari Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.